Skip to content
    ALLO
    Earnings call· Jun 2026(Q2 FY26)

    Allogene Therapeutics Q2 FY26 earnings call ALLO

    Aug 12, 2026 Source

    Executive summary

    Allogene Therapeutics Q2 FY26 — Strategic Progress in Allogeneic CAR-T and Pipeline Advancement

    Allogene Therapeutics is advancing its allogeneic CAR-T platform, focusing on clinical advantages like ready availability and local treatment. The company's strategic shift is yielding results, with Cema-Cel gaining regulatory validation and expanding site activation, while ALLO-316 shows promise in solid tumors despite safety challenges. Rapid enrollment in the ALLO-329 autoimmune trial further underscores the company's execution and program design.

    Highlights

    5

    • FDA granted RMAT and Fast Track designations for Cema-Cel in first-line consolidation, validating the ALPHA3 program and unmet medical need.

    • ALPHA3 site activation exceeded goals, reaching 80+ sites in July (goal for year-end) and now targeting approximately 100 sites by year-end.

    • ALLO-316 TRAVERSE trial showed a 31% confirmed overall response rate with durability in CD70 high renal cell carcinoma, demonstrating the Dagger platform's potential in solid tumors.

    • Cema-Cel in ALPHA3 demonstrated rapid MRD clearance in a majority of patients with no treatment-related hospitalizations, enabling outpatient treatment in community practices.

    • ALLO-329 RESOLUTION trial enrollment is progressing quickly across cohorts, dose levels, and lymphodepletion strategies.

    Concerns

    2

    • ALLO-316 program faced real safety challenges, though management developed a management algorithm to address them.

    • Achieving statistical significance at the ALPHA3 interim EFS analysis will require "overwhelming efficacy" due to alpha allocation.

    Guidance & targets

    1
    CategoryTargetConfidence
    ALPHA3 Active Clinical Sites
    approximately 100 sites active
    medium materiality
    High

    Operational metrics

    5
    ALPHA3 Patients Randomized Target
    220
    ongoing

    Target number of patients to be randomized into the two arms of the ALPHA3 study.

    ALLO-329 Patients Treated
    nine
    Q2 FY26

    Patients treated in both lymphodepletion (LD) and non-LD containing arms as of the last quarter.

    ALLO-329 Dose Levels
    20 million, 40 million, 80 million
    Q4 FY26

    First three dose cohorts to be included in the upcoming Q4 data release for the RESOLUTION trial.

    ALPHA3 Site Activation Goal (Initial)
    over 80reached in July
    FY26

    Initial goal for clinical site activation by year-end, which was achieved ahead of schedule.

    ALPHA3 Site Activation Goal (Revised)
    approximately 100
    FY26

    Revised goal for active clinical sites by year-end, reflecting increased investigator interest and strong execution.

    Industry KPIs

    3
    MetricValueDetails
    Pipeline read out calendarALLO-329 update by year-end; ALPHA3 updates throughout 2027
    Regulatory approvals filingsRMAT and Fast Track designations granted
    Clinical trial efficacy safety data31% ORR; rapid MRD clearance in majority of patients%

    Risks & headwinds

    3
    ALLO-316 safety challengesPast and ongoing

    real safety challenges

    Mitigation: Team brought in outside experts, engaged with FDA, developed management algorithm, continued learning to manage serious events.

    Competitive landscape from frontline autologous CAR-T and bispecificsOngoing

    fairly minimal impact on the overall rate of MRD positivity

    Mitigation: Management believes ALPHA3 is well-protected due to toxicity profiles and logistical burdens of competitors, which will likely reserve them for select patients/centers, leaving most community patients for ALPHA3.

    Competitive landscape from in vivo CAR-TFuture

    Not quantified, but described as "extremely exciting platform"

    Mitigation: Management believes in vivo CAR-T will primarily replace autologous CAR-T in relapsed/refractory settings, not frontline, due to toxicity and administration challenges in community settings. Allogeneic CAR-T offers advantages for community oncologists.

    What to watch in Q3 FY26

    4

    ALLO-329 Clinical and Translational Update

    By year-end 2026 (Q4 FY26)
    CurrentEnrollment progressing quickly across cohorts, dose levels, and lymphodepletion strategies. Nine patients treated as of last quarter.
    TargetClinical and translational data, including safety, efficacy, and translational findings.

    Why it matters

    This update will provide the first look at data from the RESOLUTION trial, crucial for understanding the product's profile and potential in autoimmune disease.

    Strong enrollment and execution are keeping us on track to report a clinical and translational update by year end.

    Q&A highlights

    10

    What is the purpose of the new MRD-negative observational cohort in ALPHA3, and what questions does it aim to answer?

    The cohort provides context for ALPHA3's MRD-positive patient results, allowing comparison of outcomes between MRD-positive and MRD-negative patients using the same population. It will help further characterize the MRD test prospectively.

    “We added this cohort to help provide context for the overall results of ALPHA3 looking at the MRD-positive patients. Of course, those are the ones that we randomized now into ALPHA3, so having a paired MRD-negative cohort using essentially the same patient population as this is coming into ALPHA3 itself, will give that ability to compare outcomes in the observational cohort of the MRD positive patients as ALPHA3 with the MRD negative patients as well.”

    asked by Unknown Analyst · answered by Zachary Roberts

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Shift and Allogeneic CAR-T Advantages

    Allogene has undergone a deliberate strategic shift since 2024, focusing on designing programs that leverage the unique attributes of off-the-shelf CAR-T, such as ready availability, consistent product quality, and the ability to treat patients locally. This approach aims to fill gaps existing modalities cannot, positioning allogeneic CAR-T as a distinct platform rather than a stepping stone between autologous therapy and future treatments.

    02

    ALPHA3 Program Validation and Execution

    The ALPHA3 trial, targeting high-risk LBCL patients post-first-line treatment, received RMAT and Fast Track designations from the FDA in July 2026. These designations validate MRD positivity as an unmet medical need and Cema-Cel's potential to address it. The program demonstrated rapid MRD clearance in a majority of patients with no treatment-related hospitalizations, enabling successful delivery in community practices. Site activation exceeded initial goals, with approximately 100 sites expected by year-end, reflecting growing investigator conviction.

    03

    ALLO-316 TRAVERSE Data and Dagger Platform

    The publication of TRAVERSE results for ALLO-316 in renal cell carcinoma highlighted a 31% confirmed overall response rate with durability, ranging from 8 to over 18 months, in an optimized regimen. Despite facing real safety challenges, the program advanced understanding of immunotherapy toxicity and generated foundational clinical evidence for the Dagger technology. This reinforces the company's principle of staying focused on sound biology, learning from data, and advancing science.

    04

    ALLO-329 RESOLUTION Trial Progress

    Enrollment in the ALLO-329 RESOLUTION trial for autoimmune disease has been rapid across various cohorts, dose levels, and lymphodepletion strategies. The product is designed with Dagger from the outset to function better against allo rejection by targeting activated host T cells. The objective is to identify the optimal dose regimen and understand the interplay of cell dose, lymphodepletion, and Dagger, with a clinical and translational update expected by year-end.

    05

    Leadership Transition and Future Outlook

    The call marked Dr. Zachary Roberts' first as CEO, emphasizing a new chapter built on the foundation laid by co-founder David Chang. The company anticipates the value of its strategic work to become increasingly visible over the next 12 months, with key updates for ALLO-329 by year-end and ALPHA3 throughout 2027. The ultimate standard is ensuring innovation is accessible to patients.

    AI-generated summary of the company’s earnings call. Not investment advice.